Hot Investor Mandate: Venture-to-Growth Fund Invests in Clinical-Stage Devices, Diagnostics and Regenerative Medicine

13 Dec

A large investment firm invests in venture to growth-stage startups. For their earlier stage investments, the firm will invest in medical devices, diagnostics and digital health companies. For devices and diagnostics, The firm prefers to invest in clinical-stage technologies, but will not invest in devices that require PMA approval. However, the firm is interested in regenerative medicine technologies of any stage. The firm is also interested in digital health companies at any stage. The firm is looking to invest between $5-15M for an initial investment in US-based companies.

The firm is interested in medical devices, diagnostics, digital health and regenerative medicine, but is indication agnostic within these sectors. The firm will not invest in medical devices that require PMA approval, unless they fall under the category of regenerative medicine.

The firm is a lead investor, and takes a board seat for their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Partnering Opens for RESI San Francisco: Early Stage Investors Flock to RESI to Meet Startups

6 Dec

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

San Francisco’s annual healthcare conference week starts in just over a month.  Already, hundreds of investors have signed up to attend RESI San Francisco – our largest event of the year, which serves as a dedicated venue for early stage investors to meet with startups in the biotech, medical device, diagnostic and digital health sectors.  While many of these investors cover multiple silos in their hunt for the most promising opportunities, we have highlighted some top investors in each of RESI’s core innovation sectors below.  Would you like to book up to 16 face-to-face meetings with investors on January 8thRegister online to join us at RESI.

Confirmed Therapeutics Investors

Click to See More…

 

Confirmed Medical Devices Investors

Click to See More…

 

Confirmed Diagnostics Investors

Click to See More…

 

Confirmed Digital Health Investors

Click to See More…

 

Wait! There is Still Time to Apply to RESI Innovation Challenge. Deadline Tomorrow…Go for It!

6 Dec

By Claire Jeong, Senior Research Analyst, LSN

claire

There are several important dates related to RESI San Francisco 2019 this week. With yesterday’s RESI partnering system launch, there is no doubt that our largest event of the year is closely approaching. Another date to keep in mind is tomorrow, Friday, December 7th, as Friday is the last date we are accepting applications for the RESI SF Innovation Challenge.

As usual, we will be selecting 30 finalists who are working on innovative technologies with high potential to scale in global markets. The Innovation Challenge is open to all early-stage companies in the therapeutics, medical devices, diagnostics, and digital health sectors who are actively fundraising. We will also be selecting several tech hub constituents to participate in the West Coast Innovators’ Pitch Challenge from 1:00 – 2:30 pm, where companies will be able to pitch in front of a panel of established investor judges and receive constructive feedback.

We encourage all applicants to read our article on how to be successful in the RESI Innovation Challenge. There is not much time left to apply – interested applicants, please complete your online application through our application portal here or submit your PDF application and supplementary materials by sending them to RESI@lifesciencenation.com. We look forward to receiving your submissions!

 

%d bloggers like this: